PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.99%
Revenue growth of 7.99% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
7.85%
Gross profit growth of 7.85% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
33.42%
EBIT growth of 33.42% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
36.79%
Operating income growth of 36.79% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
30.54%
Net income growth of 30.54% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
30.59%
EPS growth of 30.59% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
30.59%
Diluted EPS growth of 30.59% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.95%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 15.29%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
32.95%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 15.29%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
32.95%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 8.98%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
65.73%
Net income/share CAGR 75-90% of Medical - Pharmaceuticals median. John Neff would push for cost or revenue enhancements to match peers.
65.73%
5Y net income/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai would check that top-line growth and share count management both contribute.
65.73%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 26.79%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.30%
Inventory growth of 2.30% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
2.44%
Asset growth of 2.44% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.23%
BV/share growth of 5.23% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-36.39%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.